Latest news with #ARTFertility
Web Release
30-07-2025
- Business
- Web Release
Gulf Capital Successfully Exits ART Fertility Clinics' Middle East Operations Selling Its Stake to IVI-RMA Global, World Leader in Fertility and Assisted Reproduction.
Gulf Capital, one of the largest private equity firms investing from the GCC to the rest of Asia, announced today that it has sold its majority stake in ART Fertility Clinics' Middle East operations to IVI-RMA Global, the world's largest assisted reproduction group. The transaction is expected to generate a significant return on invested capital, making it one of Gulf Capital's most successful exits to date. Since its acquisition in 2020, ART Fertility Clinics has undergone a period of significant growth and transformation. Under Gulf Capital's ownership, ART expanded from a UAE-focused business into a regional fertility platform with 15 clinics, including 3 in the UAE, 1 in Saudi, and 11 in India. The scope of the transaction includes the clinics located in UAE and Saudi Arabia, while the India operation will remain under the ownership of Gulf Capital. In the Middle East alone, ART Fertility Clinics has delivered substantial revenue and EBITDA growth since 2020, with profitability quadrupling over the last five years. This strong financial performance has been underpinned by ART's reputation for clinical excellence, rapid regional expansion and some of the highest success rates in IVF treatments across the region. Dr. Karim El Solh, Co-Founder and CEO of Gulf Capital, commented: 'We are proud of the transformation we achieved at ART Fertility, scaling the platform from a single-country operator to the regional leader in reproductive medicine. Under Gulf Capital's ownership, ART Fertility invested heavily in science and research with 220 medical publications to date and launched a pioneering genetic testing lab in Abu Dhabi, leading to some of the highest IVF fertility success rates globally. ART Fertility's expansion and financial performance underline Gulf Capital's deep focus on operational improvements and growth. Following a competitive auction, the successful sale of the company to a global strategic buyer highlights Gulf Capital's ability to source, grow and exit healthcare platforms at very attractive multiples.' Suresh Soni, CEO of ART Fertility Clinics, said: 'ART Fertility has built a strong reputation for clinical excellence and world-class patient outcomes. Our success has been driven by our scientific rigor, a world-renowned medical team led by Prof. Dr Human Fatemi, and a deep commitment to providing the best-in-class care. With the support of Gulf Capital, we were able to expand successfully across the region and enhance our service offerings including adding in house genetic capabilities. We are excited to join IVI-RMA's global platform and to continue delivering on our mission and commitment towards the GCC community.' Hazem Abu Khalaf, Managing Director and Head of Healthcare investments at Gulf Capital, added: 'Our investment in ART Fertility is a clear example of Gulf Capital's ability to drive operational improvement and strategic growth in high-impact sectors. As one of the most vital and fast-evolving industries in the GCC, healthcare continues to offer both meaningful impact and long-term growth opportunities. ART Fertility stands as a testament to that potential. Over the past few years, we have helped build a business that combines scale, profitability, and clinical leadership – three elements that are often difficult to align. We are confident that ART Fertility is well-positioned for continued success in its next phase of growth under IVI-RMA's ownership and proud to have laid the foundation for its continued success in advancing specialized healthcare in the region' Gulf Capital and ART Fertility Clinics were advised by Moelis & Company as M&A advisor, and A&O Shearman as legal advisor on the transaction.
Zawya
30-07-2025
- Business
- Zawya
Gulf Capital successfully exits ART Fertility Clinics' Middle East operations
Abu Dhabi: Gulf Capital, one of the largest private equity firms investing from the GCC to the rest of Asia, announced today that it has sold its majority stake in ART Fertility Clinics' Middle East operations to IVI-RMA Global, the world's largest assisted reproduction group. The transaction is expected to generate a significant return on invested capital, making it one of Gulf Capital's most successful exits to date. Since its acquisition in 2020, ART Fertility Clinics has undergone a period of significant growth and transformation. Under Gulf Capital's ownership, ART expanded from a UAE-focused business into a regional fertility platform with 15 clinics, including 3 in the UAE, 1 in Saudi, and 11 in India. The scope of the transaction includes the clinics located in UAE and Saudi Arabia, while the India operation will remain under the ownership of Gulf Capital. In the Middle East alone, ART Fertility Clinics has delivered substantial revenue and EBITDA growth since 2020, with profitability quadrupling over the last five years. This strong financial performance has been underpinned by ART's reputation for clinical excellence, rapid regional expansion and some of the highest success rates in IVF treatments across the region. Dr. Karim El Solh, Co-Founder and CEO of Gulf Capital, commented: 'We are proud of the transformation we achieved at ART Fertility, scaling the platform from a single-country operator to the regional leader in reproductive medicine. Under Gulf Capital's ownership, ART Fertility invested heavily in science and research with 220 medical publications to date and launched a pioneering genetic testing lab in Abu Dhabi, leading to some of the highest IVF fertility success rates globally. ART Fertility's expansion and financial performance underline Gulf Capital's deep focus on operational improvements and growth. Following a competitive auction, the successful sale of the company to a global strategic buyer highlights Gulf Capital's ability to source, grow and exit healthcare platforms at very attractive multiples.' Suresh Soni, CEO of ART Fertility Clinics, said: 'ART Fertility has built a strong reputation for clinical excellence and world-class patient outcomes. Our success has been driven by our scientific rigor, a world-renowned medical team led by Prof. Dr Human Fatemi, and a deep commitment to providing the best-in-class care. With the support of Gulf Capital, we were able to expand successfully across the region and enhance our service offerings including adding in house genetic capabilities. We are excited to join IVI-RMA's global platform and to continue delivering on our mission and commitment towards the GCC community.' Hazem Abu Khalaf, Managing Director and Head of Healthcare investments at Gulf Capital, added: 'Our investment in ART Fertility is a clear example of Gulf Capital's ability to drive operational improvement and strategic growth in high-impact sectors. As one of the most vital and fast-evolving industries in the GCC, healthcare continues to offer both meaningful impact and long-term growth opportunities. ART Fertility stands as a testament to that potential. Over the past few years, we have helped build a business that combines scale, profitability, and clinical leadership – three elements that are often difficult to align. We are confident that ART Fertility is well-positioned for continued success in its next phase of growth under IVI-RMA's ownership and proud to have laid the foundation for its continued success in advancing specialized healthcare in the region' Gulf Capital and ART Fertility Clinics were advised by Moelis & Company as M&A advisor, and A&O Shearman as legal advisor on the transaction. About Gulf Capital Gulf Capital is an operationally focused private equity firm with over 19 years of investment experience from the GCC to the rest of Asia, one of the fastest growing investment corridors in the world today. Gulf Capital partners with dynamic entrepreneurs and exceptional management teams to provide them with growth capital, strategic advice, and operational expertise to build market leading global businesses. The Firm has a long and proven track record of investing in Growth Markets, having closed 45 investments since 2006. It currently manages over $2.4 billion in assets across seven funds and investment vehicles. As a thematic investor, Gulf Capital focuses on resilient, forward-looking sectors such as Technology and Fintech, Healthcare, Business Services, Consumer, and Sustainability. Its mission is to build value with world-class governance and ESG best practices, deep focus on operational improvements and sectoral expertise to generate sustainable and superior performance for its key stakeholders. For more information, please visit or LinkedIn @gulfcapital About ART Fertility Clinics Founded in 2015, ART Fertility Clinics is a globally recognized provider of fertility treatments, known for its clinical excellence, scientific research, and outstanding patient outcomes. The company operates across the UAE, Saudi Arabia, and India. About IVI RMA Global IVI RMA Global is a global leader in reproductive medicine, committed to delivering personalized, high-quality fertility care backed by science, technology, and compassionate care. Through its growing network of clinics, the company empowers individuals and couples to build the families they dream of—safely, effectively, and with unwavering support at every step. FOR MEDIA INFORMATION: Petra Consulting Randa Mazzawi +971 50 4506120 randa@
Economic Times
08-06-2025
- Business
- Economic Times
KKR-backed IVI to buy ART Fertility Clinics for $450 million
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.
Time of India
08-06-2025
- Business
- Time of India
KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin America. Both parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June end. As with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) valuation. ART Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and India. Live Events With clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Capital. ART Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and Faridabad. Led by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine years. According to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million. "For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well." IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals. A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to queries. Moelis is the advisor in the transaction. India is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in Europe. Infertility affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and pollution. According to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%. India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall Clinic. Nova IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and TPG. Similarly, homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.
Mint
31-05-2025
- Business
- Mint
Temasek backed Cloudnine leads race to acquire ART Fertility for $400 mn
Mumbai: Temasek-backed Cloudnine Hospitals is leading the race to acquire Art Fertility, a UAE-based IVF treatment chain, signalling a growing interest among financial and strategic investors for single-specialty healthcare companies. The deal, valuing Art Fertility at $400 million, has also seen interest from IVI, a European strategic investor, four people with knowledge of the development said on the condition of anonymity. 'The binding bids have come in. There are two final bidders. Cloudnine is likely the frontrunner," the first person cited above said. The deal will give existing investor Gulf Capital an exit. Also read: Temasek, ADIA race to invest up to $300mn in medical equipment firm Micro Life 'Temasek is expected to double down on its investment in Cloudnine to help the company fund the acquisition," the people cited above said. 'The acquisition involves ART Fertility's entire business, comprising Middle Eastern and Indian divisions." Investment bank Moelis & Co. is running the mandate for the transaction. While spokespersons for Temasek and Moelis declined to comment, queries emailed to Cloudnine, ART Fertility and Gulf Capital did not elicit any response. Temasek's new capital infusion comes less than a year after the Singapore government's investment arm bought nearly a 20% stake in Bengaluru-based Cloudnine for around $125 million. The deal, which valued the specialist mother and baby care hospital at around $600 million, gave early-stage venture capital firm Peak XV an exit from the company after 11 years. Founded in 2006 by Dr. R Kishore Kumar, Rohit M.A., M. Ramachandra and Vidya Kumar, Cloudnine is a chain of super-specialty hospitals catering to fertility, maternity care, gynaecology, paediatrics, neonatology, baby care and stem cell banking. Currently, it has 34 centres across Indian cities, including Bengaluru, Delhi, Mumbai, Pune, Chennai, Gurgaon, Ludhiana and Chandigarh. Twelve of the centres are in Bengaluru. Also read: Bain held on to Emcure after the IPO. Here's what's next. ART Fertility was established as an extension to IVI RMA Global, a company focused on assisted reproduction technology (ART), in 2015 under the brand name IVI Middle East. About five years later, Gulf Capital bought IVI RMA's stake and rebranded the company to ART Fertility. For Cloudnine, the acquisition comes at a time when it's realigning its cap table ahead of a public listing that is expected later this year. This would be the hospital chain's second attempt at an initial public offering (IPO). In 2022, it had filed draft papers for a ₹1,200 crore IPO. Cloudnine will leverage ART Fertility's presence in Abu Dhabi, Al Ain and Dubai, alongside 11 clinics across India in cities including Delhi, Chennai, Mumbai and Ahmedabad. Its clinics have seen a swift expansion to become one of the leading players in the Middle East and the Indian subcontinent, with plans to extend services further across the globe, Gulf Capital said in a statement in November 2023. Kids Clinic India Ltd, which operates Cloudnine, reported a consolidated revenue of $145.3 million in FY24 as compared with $119.8 million a year earlier. It narrowed its losses to $3.4 million from a loss of $5.3 million in FY23, according to data from Tracxn. Also read: Dialysis chain NephroPlus engages bankers for a $200-250 mn IPO ICRA noted last year that Kids Clinic will benefit from healthy revenue growth on a steady ramp-up at the existing centres and improving revenue share from new centres. The diversification of its presence across various parts of northern, western and southern India, coupled with plans to set up more units in metros and tier I cities, will also add to its growth. With continuous expansion in recent years resulting in a sizable loss from new centres, its return on capital employed (ROCE) has been low in FY23 and FY24, ICRA said in the note. However, a robust scale of operations, gradual improvement in profit margins of new centres and stable margins of existing areas will support the improvement in ROCE over the medium term, the credit rating firm said.
